 SAN FRANCISCO, Sept. 30, 2021 GLOBE NEWSWIRE -- Nurix Therapeutics, Inc. Nasdaq: NRIX, a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointments of Judith A. Reinsdorf and Paul M. Silva to its board of directors, effective October 1, 2021. Ms. Reinsdorf is the former executive vice president and general counsel of Johnson Controls International, and Mr. Silva is the former senior vice president, chief accounting officer at Vertex Pharmaceuticals Incorporated. 